Why Merck Might Have A Fight On Its Hands With Its $6.7 Billion Takeover Of Terns

Merck (MRK) made plans Wednesday to beef up its cancer treatment portfolio with the $6.7 billion acquisition of Terns Pharmaceuticals (TERN). But the takeover could be at risk. The price tag is low considering the startlingly good data Terns put out for its chronic myeloid leukemia treatment, TERN-701, William Blair analyst Andy Hsieh said. "The compound has demonstrated unequivocal improvement… Related news Philip Kotler, 94, revolutionized the way marketing is taught and studied. (Italy Photo Press/ZUMA Press/Newscom) Philip Kotler Revolutionized Marketing — And Didn't Stop There 4/01/2026 As a youngster, Philip Kotler loved books. But not the kind of books most kids read. 4/01/2026 As a youngster, Philip Kotler loved books. But not the kind of...

Dow Jones Drug Giant Merck, Costco Approach New Buy Points How Merck's New Cholesterol Buster Will 'Move The Needle' 'By Removing The Needle' Merck Stock Is Outperforming In A Volatile Market.

This Trade Puts An 11% Return In Sight.

Stock Market Rallies Again, But S 2 Health Care Stocks To Watch Google Grabs Attention, But Funds Go Crazy For This 'Pick-And-Shovel' AI Stock Dow Jones Futures Fall As Oil Keeps Surging On Iran Conflict; Jobs Report On Tap Merck Stock, Up 18% In 2026, Ticks Another Box.

Is It Now A Buy?

Dow Jones Giant Merck Crushes Fourth-Quarter Views And Shakes Off Guidance Scare